PGEN Precigen Inc

Price (delayed)

$1.22

Market cap

$311.69M

P/E Ratio

8.71

Dividend/share

N/A

EPS

$0.14

Enterprise value

$309.83M

Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases ...

Highlights
PGEN's equity has surged by 149% year-on-year and by 46% since the previous quarter
Precigen's EPS has surged by 129% YoY
PGEN's net income has surged by 126% year-on-year but it is down by 12% since the previous quarter
PGEN's quick ratio has soared by 98% from the previous quarter but it is down by 47% YoY

Key stats

What are the main financial stats of PGEN
Market
Shares outstanding
255.48M
Market cap
$311.69M
Enterprise value
$309.83M
Valuations
Price to earnings (P/E)
8.71
Price to book (P/B)
1.67
Price to sales (P/S)
12.06
EV/EBIT
10.43
EV/EBITDA
7.97
EV/Sales
13.33
Earnings
Revenue
$23.25M
EBIT
$29.71M
EBITDA
$38.89M
Free cash flow
-$67.7M
Per share
EPS
$0.14
Free cash flow per share
-$0.29
Book value per share
$0.73
Revenue per share
$0.1
TBVPS
$0.7
Balance sheet
Total assets
$241.55M
Total liabilities
$57.41M
Debt
$21.69M
Equity
$184.13M
Working capital
$91.01M
Liquidity
Debt to equity
0.12
Current ratio
2.95
Quick ratio
2.85
Net debt/EBITDA
-0.05
Margins
EBITDA margin
167.3%
Gross margin
73.5%
Net margin
106.8%
Operating margin
-325.7%
Efficiency
Return on assets
9.6%
Return on equity
19.5%
Return on invested capital
19.2%
Return on capital employed
15.2%
Return on sales
127.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PGEN stock price

How has the Precigen stock price performed over time
Intraday
1.67%
1 week
-5.43%
1 month
7.96%
1 year
-8.27%
YTD
-19.74%
QTD
15.09%

Financial performance

How have Precigen's revenue and profit performed over time
Revenue
$23.25M
Gross profit
$17.08M
Operating income
-$75.71M
Net income
$24.83M
Gross margin
73.5%
Net margin
106.8%
PGEN's net income has surged by 126% year-on-year but it is down by 12% since the previous quarter
Precigen's net margin has soared by 119% YoY
PGEN's gross profit has surged by 66% year-on-year but it is down by 17% since the previous quarter
PGEN's operating margin is up by 42% YoY but it is down by 18% from the previous quarter

Growth

What is Precigen's growth rate over time

Valuation

What is Precigen stock price valuation
P/E
8.71
P/B
1.67
P/S
12.06
EV/EBIT
10.43
EV/EBITDA
7.97
EV/Sales
13.33
Precigen's EPS has surged by 129% YoY
PGEN's equity has surged by 149% year-on-year and by 46% since the previous quarter
PGEN's P/B is 77% below its 5-year quarterly average of 7.3 and 44% below its last 4 quarters average of 3.0
PGEN's P/S is 99% below its 5-year quarterly average of 1236.1 and 11% below its last 4 quarters average of 13.5
Precigen's revenue has increased by 42% YoY but it has decreased by 14% from the previous quarter

Efficiency

How efficient is Precigen business performance
The ROIC has soared by 196% YoY and by 22% from the previous quarter
The ROA has soared by 138% YoY but it has contracted by 4% from the previous quarter
Precigen's return on sales has surged by 127% YoY
PGEN's return on equity has surged by 124% year-on-year but it is down by 31% since the previous quarter

Dividends

What is PGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PGEN.

Financial health

How did Precigen financials performed over time
PGEN's quick ratio has soared by 98% from the previous quarter but it is down by 47% YoY
PGEN's current ratio has surged by 97% since the previous quarter but it has dropped by 51% year-on-year
Precigen's debt is 88% less than its equity
PGEN's equity has surged by 149% year-on-year and by 46% since the previous quarter
PGEN's debt to equity has plunged by 96% YoY and by 71% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.